Natera, Inc. (NTRA) Trading Down 0% Following Weak Earnings
Natera, Inc. (NASDAQ:NTRA)’s share price was down 0% during mid-day trading on Thursday following a weaker than expected earnings announcement. The company traded as low as $8.66 and last traded at $9.41. Approximately 528,397 shares were traded during trading, an increase of 298% from the average daily volume of 132,774 shares. The stock had previously closed at $9.41.
The medical research company reported ($0.51) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.04). The business had revenue of $56.66 million for the quarter, compared to the consensus estimate of $55.31 million. Natera had a negative return on equity of 137.46% and a negative net margin of 62.64%. The business’s revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.50) earnings per share.
A number of analysts have recently commented on NTRA shares. Zacks Investment Research lowered Natera from a “buy” rating to a “hold” rating in a report on Thursday, October 26th. BidaskClub upgraded Natera from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. ValuEngine upgraded Natera from a “strong sell” rating to a “sell” rating in a report on Thursday, August 10th. Finally, Morgan Stanley cut their price target on Natera from $18.00 to $13.00 and set an “overweight” rating on the stock in a report on Monday, August 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $16.20.
In other news, insider Jonathan Sheena sold 120,000 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $12.54, for a total value of $1,504,800.00. Following the sale, the insider now directly owns 533,208 shares in the company, valued at $6,686,428.32. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 12.57% of the company’s stock.
Several large investors have recently added to or reduced their stakes in NTRA. Virtu KCG Holdings LLC acquired a new stake in shares of Natera in the second quarter valued at about $126,000. American International Group Inc. increased its position in shares of Natera by 7.1% in the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock valued at $142,000 after acquiring an additional 1,068 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Natera in the second quarter valued at about $151,000. Goldman Sachs Group Inc. increased its position in shares of Natera by 45.3% in the first quarter. Goldman Sachs Group Inc. now owns 17,386 shares of the medical research company’s stock valued at $154,000 after acquiring an additional 5,417 shares during the last quarter. Finally, Voya Investment Management LLC increased its position in shares of Natera by 17.8% in the second quarter. Voya Investment Management LLC now owns 14,663 shares of the medical research company’s stock valued at $159,000 after acquiring an additional 2,212 shares during the last quarter. 59.89% of the stock is currently owned by institutional investors and hedge funds.
Natera Company Profile
Receive News & Stock Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related stocks with our FREE daily email newsletter.